Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

GAO Finds Higher Pathology Service Referrals By Physicians Who Self-Refer

This article was originally published in The Gray Sheet

Executive Summary

The Government Accountability Office recommends that CMS remove financial incentives for specialists to self-refer pathology work to in-house laboratories or facilities in which they have a financial interest.

You may also be interested in...



Pathologist Group Focuses On SGR, Self-Referrals, EHRs On Capitol Hill

The College of American Pathologists is optimistic about achieving permanent reform to the Medicare physician payment system based on Senate Finance Chair Ron Wyden’s laser focus on the issue. Jonathan Myles, who chairs CAP’s economic affairs committee, discussed the group’s legislative priorities.

Self-Referral Drives Extra Prostate Biopsy Activity, Study Suggests

A Medicare claims analysis compared biopsy trends in men referred for biopsy analysis by urologists who use a pathology lab to which they have a financial association, and those who see urologists that order biopsies at unassociated labs.

Japan Regulatory Update: Revised Law Widens RWD Scope, Price Revisions/Listings

Japan now allows pseudonymized personal data for medical use under a licensing system for wider use of real-world data. Meanwhile, a national cost-effectiveness assessment scheme has slashed reimbursement prices for Lagevrio and Kerendia, and Alexion’s Voydeya has been added to the reimbursement tariff.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT032249

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel